Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus anlotinib in platinum-resistant recurrent ovarian cancer
ChiCTR2000030726Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of niraparib and anlotinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Feb 2020; status: recruiting.
02
Drugs
niraparibanlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2000030726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030726.